SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will participate on a panel at the Cantor Global Healthcare Conference. The panel discussion will take place in New York on Wednesday, September 27, 2023, at 8:00 am ET.
A live webcast of the panel can be accessed by visiting the Company’s Events & Presentations webpage or by clicking here. A replay will be available on the Company’s website following the event.
Institutional investors interested in meeting with management during the conference may reach out to their Cantor Fitzgerald representative.
About Elutia
Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.13 |
| Daily Change: | -0.17 -3.95 |
| Daily Volume: | 63,363 |
| Market Cap: | US$122.870M |
September 05, 2024 August 07, 2024 August 01, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
